Secondary analysis of two phase III trials (7914 patients with HR+/HER2- early breast cancer): endocrine response after 2-4 weeks of preoperative therapy was higher with aromatase inhibitors than tamoxifen (81.4% vs 40.1% and 76.7% vs 34.7%).
Secondary analysisn = 7,914
Gluz et al. Clinical and molecular biomarkers for prediction of endocrine response after short preoperative endocrine therapy in the WSG ADAPT-HR+/HER2- and ADAPTcycle trials (N = 7914)